EDWARDS LIFESCIENCES CORP (EW) Stock Price, Forecast & Analysis
USA - New York Stock Exchange - NYSE:EW - US28176E1082 - Common Stock
EW Key Statistics, Chart & Performance
The current stock price of EW is 85.25 USD. In the past month the price increased by 0.64%. In the past year, price increased by 15.34%.
EW Latest News, Press Relases and Analysis
EW Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 25.11 | 217.86B | ||
| ISRG | INTUITIVE SURGICAL INC | 65.78 | 200.77B | ||
| BSX | BOSTON SCIENTIFIC CORP | 32.32 | 141.35B | ||
| SYK | STRYKER CORP | 26.69 | 134.41B | ||
| BDX | BECTON DICKINSON AND CO | 13.46 | 55.39B | ||
| IDXX | IDEXX LABORATORIES INC | 53.65 | 54.02B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 17.87 | 37.36B | ||
| RMD | RESMED INC | 24.33 | 35.16B | ||
| DXCM | DEXCOM INC | 35.68 | 25.89B | ||
| PODD | INSULET CORP | 62.2 | 20.00B | ||
| ZBH | ZIMMER BIOMET HOLDINGS INC | 11.11 | 17.82B | ||
| HOLX | HOLOGIC INC | 17.44 | 16.60B |
Related stock screener links
About EW
Company Profile
Edwards Lifesciences Corp. engages in patient-focused medical innovations for heart disease and critical care monitoring. The company is headquartered in Irvine, California and currently employs 15,800 full-time employees. The company went IPO on 2000-03-27. The firm partners with clinicians and researchers and invests in research and development to improve care for those impacted by structural heart disease. Its product categories include Transcatheter Aortic Valve Replacement (TAVR), Transcatheter Mitral and Tricuspid Therapies (TMTT), and Surgical Structural Heart. The company provides transcatheter heart valve replacement technologies designed for the minimally-invasive replacement of aortic heart valves. TAVR category includes the Edwards SAPIEN 3, the Edwards SAPIEN 3 Ultra and the Edwards SAPIEN 3 Ultra RESILIA systems. TMTT category includes the PASCAL Precision transcatheter repair system, EVOQUE tricuspid valve replacement system and Cardioband tricuspid valve reconstruction system. Its INSPIRIS RESILIA aortic valve, offers RESILIA tissue and VFit technology. The company is managed in various geographical regions, such as United States, Europe, Japan and Rest of World.
Company Info
EDWARDS LIFESCIENCES CORP
One Edwards Way
Irvine CALIFORNIA 92614 US
CEO: Michael A. Mussallem
Employees: 15800
Phone: 19492502500
EDWARDS LIFESCIENCES CORP / EW FAQ
What does EW do?
Edwards Lifesciences Corp. engages in patient-focused medical innovations for heart disease and critical care monitoring. The company is headquartered in Irvine, California and currently employs 15,800 full-time employees. The company went IPO on 2000-03-27. The firm partners with clinicians and researchers and invests in research and development to improve care for those impacted by structural heart disease. Its product categories include Transcatheter Aortic Valve Replacement (TAVR), Transcatheter Mitral and Tricuspid Therapies (TMTT), and Surgical Structural Heart. The company provides transcatheter heart valve replacement technologies designed for the minimally-invasive replacement of aortic heart valves. TAVR category includes the Edwards SAPIEN 3, the Edwards SAPIEN 3 Ultra and the Edwards SAPIEN 3 Ultra RESILIA systems. TMTT category includes the PASCAL Precision transcatheter repair system, EVOQUE tricuspid valve replacement system and Cardioband tricuspid valve reconstruction system. Its INSPIRIS RESILIA aortic valve, offers RESILIA tissue and VFit technology. The company is managed in various geographical regions, such as United States, Europe, Japan and Rest of World.
What is the current price of EW stock?
The current stock price of EW is 85.25 USD. The price decreased by -1.1% in the last trading session.
Does EDWARDS LIFESCIENCES CORP pay dividends?
EW does not pay a dividend.
How is the ChartMill rating for EDWARDS LIFESCIENCES CORP?
EW has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 7 out of 10.
How is the valuation of EDWARDS LIFESCIENCES CORP (EW) based on its PE ratio?
The PE ratio for EDWARDS LIFESCIENCES CORP (EW) is 33.17. This is based on the reported non-GAAP earnings per share of 2.57 and the current share price of 85.25 USD.
What is the Short Interest ratio of EDWARDS LIFESCIENCES CORP (EW) stock?
The outstanding short interest for EDWARDS LIFESCIENCES CORP (EW) is 0.98% of its float.
EW Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to EW. When comparing the yearly performance of all stocks, EW is one of the better performing stocks in the market, outperforming 78.91% of all stocks.
EW Fundamental Analysis
ChartMill assigns a fundamental rating of 7 / 10 to EW. Both the health and profitability get an excellent rating, making EW a very profitable company, without any liquidiy or solvency issues.
EW Financial Highlights
Over the last trailing twelve months EW reported a non-GAAP Earnings per Share(EPS) of 2.57. The EPS decreased by -3.75% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 23.25% | ||
| ROA | 10.31% | ||
| ROE | 13.4% | ||
| Debt/Equity | 0.06 |
EW Forecast & Estimates
42 analysts have analysed EW and the average price target is 97.12 USD. This implies a price increase of 13.92% is expected in the next year compared to the current price of 85.25.
For the next year, analysts expect an EPS growth of 1.51% and a revenue growth 4.63% for EW